View Post

Drug price controls will stifle innovation: Pharmaceutical industry R&D is saving lives

In In The News by Barbara Jacoby

By: Sally Pipes From: nydailynews.com This year, 1.7 million Americans will be diagnosed with cancer. For over 600,000 of them, that diagnosis will prove fatal. But there’s hope on the horizon. More Americans are surviving cancer each year, according to a new study from the American Cancer Society. The cancer death rate declined precipitously between its peak in 1991 and …

View Post

The Bigger Picture

In In The News by Barbara Jacoby

By: Josh Bramwell From: eyeforpharma.com Merck’s Chief Medical Officer reflects on his career thus far and weighs in on the industry’s biggest opportunities and challenges. As an academic physician, scientist and R&D executive, Steven Hildemann is highly qualified to comment on the big issues and challenges that will define the pharma industry for years to come. Hildemann’s career trajectory can …

View Post

Cell Medica, Baylor partner on next-gen CAR-T cancer therapies

In In The News by Barbara Jacoby

By: Ben Adams From: fiercebiotech.com London-based Cell Medica, one of last year’s Fierce 15, has signed a pact with Houston’s Baylor College of Medicine to find and develop next-gen tech for engineering immune cells in tumors. In a joint statement, the two saw the “ground-breaking” co-development partnership will see Cell Medica gain an exclusive license over several Baylor cell and …

CytRx is pouring money into R&D of cancer-fighting drugs

In In The News by Barbara Jacoby

By Shashank Bengali From: latimes.com CytRx Corp. is on a mission to cure cancer — or at least slow it down. The Los Angeles biopharmaceutical company, which recently has become embroiled in a stock-promotion controversy, specializes in researching and developing drugs to treat cancers. The most promising medication, aldoxorubicin, is a more advanced version of the widely used chemotherapy drug …